It has been reported that antagonizing TGF-β signaling or angiotensin II signaling suppresses the development of aneurysms in Fbn1 mutant mice or Marfan syndrome patients, even though these drugs does not correct the structural problems in microfibrils caused by mutant fibrillin-125. This evidence concerns the gene AGT and Marfan syndrome.